Peptide Cycling Strategies

What peptide cycling means

Peptide cycling means using a compound for a set block of weeks, then taking a planned break. The habit comes from anabolic steroid culture, where off-periods are meant to let natural testosterone production restart. With peptides the reasons are different, and most haven't been tested in people.

Most of the discussion concerns growth hormone (GH) secretagogues, the peptides that prompt the pituitary to release more of its own GH. The articles in this section go further, starting with a comparison of standard cycles and blast-and-cruise approaches.

Why people cycle

Receptor desensitization

The reason given most often is desensitization: the idea that a receptor under constant stimulation becomes less responsive, so the same dose does less over time. Ipamorelin, hexarelin and MK-677 all act on the ghrelin receptor (GHSR-1a), a G-protein-coupled receptor. Many receptors in that family lose responsiveness under sustained stimulation, so the concern is plausible. Whether it matters at the doses users take is a separate question.

Recovery of the body's own hormones

Users often borrow the steroid logic that a break lets natural production recover. It fits poorly here: secretagogues don't replace GH, they push the pituitary to release its own. The closest human data on recovery is the hexarelin study below, where the GH response was back to baseline four weeks after stopping.

Side effects and lab drift

Some people cycle to limit cumulative exposure. In a 2-year MK-677 trial, fasting glucose rose by about 5 mg/dL, insulin sensitivity fell, and cortisol rose. Users often say a break lets blood work settle, but we couldn't find a study that tested whether an off-period reverses these changes. The long-term effects of repeated cycles get their own article.

What human studies show

Hexarelin over 16 weeks

In a 1998 study, 12 healthy older adults injected hexarelin under the skin twice daily for 16 weeks. Their GH response (area under the curve, in µg/L per hour) fell from 19.1 at baseline to 13.1 at week 1, 12.3 at week 4 and 10.5 at week 16, a drop of about 45%. Four weeks after the course ended, a repeat dose produced a response of 19.4, statistically no different from the start. The authors described the attenuation as "partial and reversible."

MK-677 over 2 years

In a randomized, placebo-controlled trial of 65 healthy adults aged 60-81, 25 mg of oral MK-677 once daily raised GH and IGF-1 to levels typical of healthy young adults. The main results came at 12 months, and a 2-year exploratory analysis confirmed them, with daily use and no breaks. Fat-free mass rose about 1.1 kg, but strength and function didn't change.

CJC-1295 with DAC

CJC-1295 with DAC is a long-acting analog of growth hormone-releasing hormone (GHRH) that binds to albumin. In two 2006 trials in healthy adults aged 21-61, its half-life was 5.8-8.1 days. After multiple weekly or every-other-week doses, IGF-1 stayed above baseline for up to 28 days, and the authors saw signs of a cumulative effect rather than a fading one.

A separate 2006 study by Ionescu and Frohman gave men aged 20-40 a single injection of 60 or 90 µg/kg and sampled their blood every 20 minutes overnight one week later. GH pulses kept their normal frequency and size, while trough GH rose about 7.5-fold and mean GH about 46%. That runs against the forum claim that DAC turns GH release into a constant "bleed," though it covered only one week after one dose.

What the studies add up to

These studies point to partial, reversible tolerance with hexarelin and no clear loss of effect for MK-677 or CJC-1295 over the periods tested. All were small. The hexarelin and MK-677 studies enrolled older adults, whose GH output is lower than a young lifter's. None compared a cycled schedule with continuous use.

Where users and studies differ

On hexarelin, forum reports and the 1998 study roughly agree. In a 2018 AnabolicMinds thread, one user wrote that people "desensitize to Hexarelin pretty quick, I think like 4 weeks roughly," which fits the significant drop the study found by week 4.

For ipamorelin and MK-677, the gap runs the other way. Cycling is the default in most community and vendor guides, yet the only long trial of a ghrelin-receptor agonist found MK-677 still raising GH and IGF-1 after two years of daily use. One telehealth vendor's ipamorelin guide concedes that "no large randomized human trial has directly demonstrated desensitization with continuous ipamorelin dosing," and recommends cycling anyway as a precaution.

A few things could explain fading effects that trials didn't show. People may get used to early changes such as deeper sleep. Gray-market vials vary in content, so a new vial can feel weaker than the last. And people who feel a drop-off are more likely to post about it.

Schedules users and vendors describe

The schedules below come from forum threads and vendor guides. As of October 2026, no trial has tested any of them against continuous use. For schedules by peptide class, see cycling protocols for bodybuilders.

In a January 2026 AnabolicMinds thread, a user planning 12 weeks on and 4 off said 5-on, 2-off was what "about every spot I saw showed," and a reply argued there was "zero need" for it except to cut cost. The vendor guide quoted above calls the evidence for 5-on, 2-off "almost entirely anecdotal." Many guides also describe tapering the dose at the end of a block. We found no study that tested whether a taper changes anything for a GH secretagogue.

Many users also time injections away from meals, believing food blunts the GH response; see eating around a peptide cycle.

Healing peptides follow a different logic

BPC-157 and TB-500 usually aren't cycled for receptor reasons. Users tend to run them for the length of an injury and then stop. A 2025 systematic review of BPC-157 in sports medicine found 35 preclinical studies and only one small clinical study, with no clinical safety data. That leaves no human basis for choosing a block length.

Stacking inside a cycle

Many users combine peptides within one block, most often a GHRH analog such as CJC-1295 without DAC (also sold as Mod GRF 1-29) with a GHRP such as ipamorelin. We found no controlled human trial of that combination. Stacking two GH-raising compounds may add to side effects like the leg swelling and higher glucose seen in the MK-677 trial, though no study has measured it. One vendor guide suggests starting and stopping both peptides together so it's easier to judge each one. See how users structure stacks within a cycle for the combinations.

Monitoring during and between cycles

Forum guides commonly describe blood work before a block and again after the off-period. For GH secretagogues, the markers with trial data behind them are IGF-1, which MK-677 and CJC-1295 both raised, and fasting glucose, which rose with MK-677. The vendor guide cited here suggests IGF-1, fasting glucose and HbA1c every 6-12 months for people running repeated cycles. Our page on baseline and on-cycle lab tests explains each marker.

What we still don't know

• As of October 2026, no trial has compared cycled and continuous use of any GH secretagogue.
• Only hexarelin and MK-677 have human data on how the GH response holds up over months. Ipamorelin, GHRP-2 and GHRP-6 haven't been measured.
• The one human data point on off-period length is full recovery four weeks after a 16-week hexarelin course. Shorter breaks, and the 5-on, 2-off pattern, haven't been studied.
• Nobody has tested whether a break reverses the glucose and insulin changes seen with MK-677.
• Some guides say older users need longer breaks. We found no data on that, and because the long studies enrolled people over 60, how younger lifters respond is also unknown.